Pelvic floor dysfunction in endometrial cancer patients after treatment. A literature review

Endometrial cancer (EC) survivors are increasing progressively. However, treating this disorder may detrimentally affect the pelvic organs, resulting in pelvic floor disorders (PFD): urinary incontinence, pelvic organ prolapse, and bowel dysfunction. The aim of this review is to investigate the prevalence of PFD in EC survivors following both surgical and nonsurgical treatments. The authors conducted a structured search in the following databases: MEDLINE, EMBASE, Global Health, The Cochrane Library, and Web of Science from inception until August 2021. The inclusion criteria were: (1) women with EC, (2) observational studies, (3) original data, (4) PFD result evaluation, and (5) the use of verified tools for the evaluation of PFD. The initial search found 590 articles for PFD and endometrial cancer. Only 10 of the studies were finally available for further analysis, including 1849 individuals with EC. In total, the incidence of UI increased from 7.6% to 20.8% after EC therapy. The incidence of stress and urge UI after treatment ranged from 23 to 74.3% and 20.8 to 71.4%, respectively. The prevalence of POP was as high as 13.6% in 638 EC survivors. The prevalence of fecal incontinence was 21% in 732 EC survivors. In conclusion, PFDs are common after endometrial cancer treatment. The lack of comparative studies between the type of EC and the type of treatment limits further exploration of the differences in PFD frequency among EC survivors and the variety of EC treatments.

Endometrial cancer (survivors); Pelvic floor disorders; Urinary incontinence; Stress urge urinary incontinence; Overactive bladder; Fecal incontinence

[1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA: A Cancer Journal for Clinicians. 2015; 65: 5–29.

[2] Wartko P, Sherman ME, Yang HP, Felix AS, Brinton LA, Trabert B. Recent changes in endometrial cancer trends among menopausalage U.S. women. Cancer Epidemiology. 2013; 37: 374–377.

[3] Bhaskaran K, Douglas I, Forbes H, dos-Santos-Silva I, Leon DA, Smeeth L. Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5ꞏ24 million UK adults. The Lancet. 2014; 384: 755–765.

[4] Mozumdar A, Liguori G. Persistent increase of prevalence of metabolic syndrome among U.S. adults: NHANES III to NHANES 1999-2006. Diabetes Care. 2011; 34: 216–219.

[5] Jamal A, Agaku IT, O’Connor E, King BA, Kenemer JB, Neff L. Current cigarette smoking among adults–United States, 2005–2013. Morbidity and Mortality Weekly Report. 2014; 63: 1108–1112.

[6] Wright JD, Herzog TJ, Tsui J, Ananth CV, Lewin SN, Lu Y, et al. Nationwide Trends in the Performance of Inpatient Hysterectomy in the United States. Obstetrics & Gynecology. 2013; 122: 233–241.

[7] SEER. SEER Cancer Stat Facts: Endometrial Cancer. Bethesda, MD 2017. Available at: http://seer.cancer.gov/statfacts/html/cor p. html (Accessed: 19 December 2021).

[8] Münstedt K, Wagner M, Kullmer U, Hackethal A, Franke FE. Influence of body mass index on prognosis in gynecological malignancies. Cancer Causes & Control. 2008; 19: 909–916.

[9] Creasman W, Odicino F, Maisonneuve P, Quinn M, Beller U, Benedet J, et al. Carcinoma of the corpus uteri. FIGO 26th annual report on the results of treatment in gynecological cancer. International Journal of Gynecology & Obstetrics. 2006; 95: S105–S143.

[10] Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, et al. Cancer treatment and survivorship statistics, 2016. CA: A Cancer Journal for Clinicians. 2016; 66: 271–289.

[11] Rutledge TL, Heckman SR, Qualls C, Muller CY, Rogers RG. Pelvic floor disorders and sexual function in gynecologic cancer survivors: a cohort study. American Journal of Obstetrics and Gynecology. 2010; 203: 514.e1–514.e7.

[12] Schünemann HJ, Vist GE, Higgins JP, Santesso N, Deeks JJ, Glasziou P, et al. Interpreting results and drawing conclusions. Cochrane Handbook for Systematic Reviews of Interventions (eds J.P. Higgins, J. Thomas, J. Chandler, M. Cumpston, T. Li,M. J. Page and V.A. Welch). 2019; 3: 403–431.

[13] Higgs P, Janda M, Asher R, Gebski V, Forder P, Obermair A. Pelvic floor functional outcomes after total abdominal versus total laparoscopic hysterectomy for endometrial cancer. American Journal of Obstetrics and Gynecology 2018; 218: 419.e1– 419. e14.

[14] Lipetskaia L, Sharma S, Johnson MS, Ostergard DR, Francis S. Urinary incontinence and quality of life in endometrial cancer patients after robotic-assisted laparoscopic hysterectomy with lymph node dissection. Journal of Obstetrics and Gynaecology. 2019; 39: 986–990.

[15] Ziętek-Strobl A, Futyma K, Kuna-Broniowska I, Wojtaś M, Rechberger T. Urogynaecological Symptoms among Oncological Survivors and Impact of Oncological Treatment on Pelvic Floor Disorders and Lower Urinary Tract Symptoms. A Six-Month Follow-Up Study. Journal of Clinical Medicine. 2020; 9: 2804.

[16] Bernard S, Moffet H, Plante M, Ouellet M, Leblond J, Dumoulin C. Pelvic-Floor Properties in Women Reporting Urinary Incontinence after Surgery and Radiotherapy for Endometrial Cancer. Physical Therapy. 2017; 97: 438–448.

[17] Nosti PA, McDermott CD, Schilder JM, Stehman FB, Woodman PJ. Symptoms of Pelvic Floor Disorders and Quality of Life Measures in Postoperative Patients with Endometrial Cancer. Clinical Ovarian and Other Gynecologic Cancer. 2012; 5: 27–30.

[18] de Boer SM, Nout RA, Jürgenliemk-Schulz IM, Jobsen JJ, Lutgens LCHW, van der Steen-Banasik EM, et al. Long-Term Impact of Endometrial Cancer Diagnosis and Treatment on Health-Related Quality of Life and Cancer Survivorship: Results from the Randomized PORTEC-2 Trial. International Journal of Radiation Oncology, Biology, Physics. 2015; 93: 797–809.

[19] Segal S, John G, Sammel M, Andy UU, Chu C, Arya LA, et al. Urinary incontinence and other pelvic floor disorders after radiation therapy in endometrial cancer survivors. Maturitas. 2017; 105: 83–88.

[20] de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C, et al. Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial. The Lancet Oncology. 2016; 17: 1114–1126.

[21] Erekson EA, Sung VW, DiSilvestro PA, Myers DL. Urinary symptoms and impact on quality of life in women after treatment for endometrial cancer. International urogynecology journal and Pelvic Floor Dysfunction. 2009; 20: 159–163.

[22] Bretschneider CE, Doll KM, Bensen JT, Gehrig PA, Wu JM, Geller EJ. Prevalence of pelvic floor disorders in women with suspected gynecological malignancy: a survey-based study. International Urogynecology Journal. 2016; 27: 1409–1414.

[23] Fitzsimmons D, Gilbert J, Howse F, Young T, Arrarras J, Brédart A, et al. A systematic review of the use and validation of health-related quality of life instruments in older cancer patients. European Journal of Cancer. 2009; 45: 19–32.

[24] Rajamanoharan S, Duncan T, Abu J. The well-being of women following total laparoscopic hysterectomy versus total abdominal hysterectomy for endometrial cancer. Gynecological Surgery. 2012; 9: 335–345.

[25] Becker M, Malafy T, Bossart M, Henne K, Gitsch G, Denschlag D. Quality of life and sexual functioning in endometrial cancer survivors. Gynecologic Oncology. 2011; 121: 169–173.

[26] Quick AM, Seamon LG, Abdel-Rasoul M, Salani R, Martin D. Sexual function after intracavitary vaginal brachytherapy for early-stage endometrial carcinoma. International Journal of Gynecological Cancer. 2012; 22: 703–708.

[27] Foerster R, Schnetzke L, Bruckner T, Arians N, Rief H, Debus J, et al. Prognostic factors for long-term quality of life after adjuvant radiotherapy in women with endometrial cancer. Strahlen-therapie Und Onkologie. 2016; 192: 895–904.

[28] Smits A, Lopes A, Das N, Bekkers R, Galaal K. The impact of BMI on quality of life in obese endometrial cancer survivors: does size matter? Gynecologic Oncology. 2014; 132: 137–141.

[29] Karabuga H, Gultekin M, Tulunay G, Yuce K, Ayhan A, Yuce D, et al. Assessing the Quality of Life in Patients with Endometrial Cancer Treated with Adjuvant Radiotherapy. International Journal of Gynecological Cancer. 2015; 25: 1526–1533.

[30] Gao H, Xiao M, Bai H, Zhang Z. Sexual Function and Quality of Life among Patients with Endometrial Cancer after Surgery. International Journal of Gynecological Cancer. 2018; 27: 608–612.

[31] Robinson KM, Christensen KB, Ottesen B, Krasnik A. Diagnostic delay, quality of life and patient satisfaction among women diagnosed with endometrial or ovarian cancer: a nationwide Danish study. Quality of Life Research. 2012; 21: 1519–1525.

[32] Angioli R, Plotti F, Cafà EV, Dugo N, Capriglione S, Terranova C, et al. Quality of life in patients with endometrial cancer treated with or without systematic lymphadenectomy. European Journal of Obstetrics, Gynecology, and Reproductive Biology. 2013; 170: 539–543.

[33] White AJ, Reeve BB, Chen RC, Stover AM, Irwin DE. Urinary incontinence and health-related quality of life among older Americans with and without cancer: a crosssectional study. BMC Cancer. 2013; 13: 377.

[34] Barber MD, Walters MD, Cundiff GW. Responsiveness of the Pelvic Floor Distress Inventory (PFDI) and Pelvic Floor Impact Questionnaire (PFIQ) in women undergoing vaginal surgery and pessary treatment for pelvic organ prolapse. American Journal of Obstetrics and Gynecology. 2006; 194: 1492–1498.

[35] Aerts L, Enzlin P, Verhaeghe J, Poppe W, Vergote I, Amant F. Sexual functioning in women after surgical treatment for endometrial cancer: a prospective controlled study. The Journal of Sexual Medicine. 2015; 12: 198–209.

[36] Nout RA, van de Poll-Franse LV, Lybeert MLM, Wárlám-Rodenhuis CC, Jobsen JJ, Mens JWM, et al. Long-term out-come and quality of life of patients with endometrial carcinoma treated with or without pelvic radiotherapy in the post operative radiation therapy in endometrial carcinoma 1 (PORTEC-1) trial. Journal of Clinical Oncology. 2011; 29: 1692–1700.

[37] Ceccaroni M, Roviglione G, Spagnolo E, Casadio P, Clarizia R, Peiretti M, et al. Pelvic dysfunctions and quality of life after nerve-sparing radical hysterectomy: a multicenter comparative study. Anticancer Research. 2012; 32: 581–588.

[38] Rutledge TL, Heckman SR, Qualls C, Muller CY, Rogers RG. Pelvic floor disorders and sexual function in gynecologic cancer survivors: a cohort study. American Journal of Obstetrics and Gynecology. 2010; 203: 514.e1–514.e7.

[39] Thomas SG, Sato HRN, Glantz JC, Doyle PJ, Buchsbaum GM. Prevalence of symptomatic pelvic floor disorders among gynecologic oncology patients. Obstetrics and Gynecology. 2013; 122: 976–980.

[40] Manchana T, Prasartsakulchai C, Santingamkun A. Long-term lower urinary tract dysfunction after radical hysterectomy in patients with early postoperative voiding dysfunction. International Urogynecology Journal. 2010; 21: 95–101.

[41] Yeoh E, Sun WM, Russo A, Ibanez L, Horowitz M. A retrospective study of the effects of pelvic irradiation for gynecological cancer on anorectal function. International Journal of Radiation Oncology, Biology, Physics. 1996; 35: 1003–1010.

[42] Donovan KA, Boyington AR, Judson PL, Wyman JF. Bladder and bowel symptoms in cervical and endometrial cancer survivors. Psycho-Oncology. 2014; 23: 672–678.

[43] Brooks RA, Wright JD, Powell MA, Rader JS, Gao F, Mutch DG, et al. Long-term assessment of bladder and bowel dysfunction after radical hysterectomy. Gynecologic Oncology. 2009; 114: 75–79.

[44] Plotti F, Zullo MA, Sansone M, Calcagno M, Bellati F, Angioli R, et al. Post radical hysterectomy urinary incontinence: a prospective study of transurethral bulking agents injection. Gynecologic Oncology. 2009; 112: 90–94.

[45] Bosch JLHR, Norton P, Jones JS. Should we screen for and treat lower urinary tract dysfunction after major pelvic surgery? ICIRS 2011. Neurourology and Urodynamics. 2012; 31: 327–329.

[46] Pisani C, Deantonio L, Surico D, Brambilla M, Galla A, Ferrara E, et al. Quality of life in patients treated by adjuvant radiotherapy for endometrial and cervical cancers: correlation with dosevolume parameters. Clinical & Translational Oncology. 2016; 18: 901–908.

[47] Mirabeau-Beale KL, Viswanathan AN. Quality of life (QOL) in women treated for gynecologic malignancies with radiation therapy: a literature review of patient-reported outcomes. Gynecologic Oncology. 2014; 134: 403–409.

[48] Vaz AF, Pinto-Neto AM, Conde DM, Costa-Paiva L, Morais SS, Esteves SB. Quality of life and acute toxicity of radiotherapy in women with gynecologic cancer: a prospective longitudinal study. Archives of Gynecology and Obstetrics. 2008; 278: 215–223.

[49] Fang P, Tan KS, Grover S, McFadien MK, Troxel AB, Lin L. Psychosocial encounters correlates with higher patient-reported functional quality of life in gynaecological cancer patients receiving radiotherapy. Radiation Oncology. 2015; 10: 34.

[50] Stinesen Kollberg K, Waldenström A, Bergmark K, Dunberger G, Rossander A, Wilderäng U, et al. Reduced vaginal elasticity, reduced lubrication, and deep and superficial dyspareunia in irradiated gynecological cancer survivors. Acta Oncologica. 2015; 54: 772–779.

[51] Soisson S, Ganz PA, Gaffney D, Rowe K, Snyder J, Wan Y, et al. Long-term, adverse genitourinary outcomes among endometrial cancer survivors in a large, population-based cohort study. Gynecologic Oncology. 2018; 148: 499–506.

[52] Creutzberg CL, van Putten WL, Koper PC, Lybeert ML, Jobsen JJ, Wárlám-Rodenhuis CC, et al. The morbidity of treatment for patients with Stage i endometrial cancer: results from a randomized trial. International Journal of Radiation Oncology, Biology, Physics. 2002; 51: 1246–1255.

[53] Lind H, Waldenström A, Dunberger G, al-Abany M, Alevronta E, Johansson K, et al. Late symptoms in long-term gynaecological cancer survivors after radiation therapy: a population-based cohort study. British Journal of Cancer. 2011; 105: 737–745.

[54] Sorbe BG, Horvath G, Andersson H, Boman K, Lundgren C, Pettersson B. External pelvic and vaginal irradiation versus vaginal irradiation alone as postoperative therapy in medium-risk endometrial carcinoma: a prospective, randomized study–quality-of-life analysis. International Journal of Gynecological Cancer. 2012; 22: 1281–1288.

[55] Herwig R, Bruns F, Strasser H, Pinggera GM, Micke O, Rehder P, et al. Late urologic effects after adjuvant irradiation in stage i endometrial carcinoma. Urology. 2004; 63: 354–358.

[56] Onsrud M, Cvancarova M, Hellebust TP, Tropé CG, Kristensen GB, Lindemann K. Long-Term Outcomes after Pelvic Radiation for Early-Stage Endometrial Cancer. Journal of Clinical Oncology. 2013; 31: 3951–3956.

[57] Del Priore G, Taylor SY, Esdaile BA, Masch R, Martas Y, Wirth J. Urinary incontinence in gynecological oncology patients. International Journal of Gynecological Cancer. 2005; 15: 911–914.

[58] Kadar N, Saliba N, Nelson JH. The frequency, causes and prevention of severe urinary dysfunction after radical hysterectomy. British Journal of Obstetrics and Gynaecology. 1983; 90: 858–863.

[59] Skjeldestad FE, Hagen B. Long-term consequences of gynecologic cancer treatment on urinary incontinence: a population-based cross sectional study. Acta Obstetricia et Gynecologica Scandinavica. 2008; 87: 469–475.

[60] Hall E, Robison K, Wohlrab K. Pelvic floor disorders in women with gynecologic malignancy. Current Opinion in Obstetrics & Gynecology. 2018; 30: 446–450.